TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03595280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hookah tobacco risk messages
Description: Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hookah tobacco risk messages
Description: Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
Study: NCT02890680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Study: NCT04409938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
Study: NCT02205489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aciclovir
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04409938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Sounds
Description: PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
Study: NCT03629483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h (equivalent to a dexmedetomidine infusion at a rate of 0.075 ug/kg/h).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
Study: NCT01238692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL).
Study: NCT03246633

Intervention type: OTHER
Group type: OTHER
Intervention: Perceptual Training
Description: Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
Study: NCT01818297

Intervention type: DEVICE
Group type: OTHER
Intervention: PrimeAdvanced® neurostimulator system
Description: Neurostimulator and associated components

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrimeAdvanced® neurostimulator system
Description: Neurostimulator and associated components
Study: NCT03044860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE) with biopsy retrieval
Description: With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE) with biopsy retrieval
Description: With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine
Study: NCT02314507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gua sha
Description: A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
Study: NCT00890838

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven-IV FO
Description: will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
Study: NCT00217165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taurine
Description: taurine 2mg BID po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taurine
Description: taurine 2mg BID po
Study: NCT01950832

Intervention type: OTHER
Intervention: Investigating clinically normal patients with optic coherence tomography

Intervention type: OTHER
Intervention: Investigating clinically normal patients with optic coherence tomography
Study: NCT02035826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Economics Intervention
Description: Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Economics Intervention
Description: Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Economics Intervention
Description: Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
Study: NCT00832897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal collagen crosslinking
Description: The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Corneal collagen crosslinking
Description: The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop.
Study: NCT01014403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Enoxaparin 30 mg sq q 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vehicle
Study: NCT01896960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 15 micrograms of fentanyl
Description: Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 15 micrograms of fentanyl
Description: Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
Study: NCT00481065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a
Study: NCT02205489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00481065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH5N1 + eTIV_a
Study: NCT04167475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Description: Each probiotic capsule contains 1 x 10\^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
Study: NCT03693248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two cycles of neoadjuvant chemotherapy
Description: Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
Study: NCT02137967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NaOCl pulpotomy
Description: Use 2.5% NaOCl as pulpotomy medicament for primary molars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FC pulpotomy
Description: Use 20% Formocresol as pulpotomy medicament for primary molars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Formocresol
Study: NCT04251364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Daily acetazolamide pill intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Daily atorvastatin pill intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily placebo pill intake
Study: NCT03604185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choir Singing
Description: A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Appreciation
Description: A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
Study: NCT04360967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Formula
Description: Standard Formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched Formula
Description: Nutrient-enriched Formula
Study: NCT01493180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 ophthalmic suspension
Description: OPC-12759 ophthalmic suspension 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate ophthalmic solution
Description: Sodium hyaluronate ophthalmic solution 0.1%
Study: NCT01401504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3026
Description: oral
Study: NCT02629731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom orthoses with varying degrees of hindfoot posting
Description: The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
Study: NCT02359981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: An Android Smartphone with operating system version higher than 2.2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: An Android Smartphone with operating system version higher than 2.2
Study: NCT01410630

Intervention type: DIAGNOSTIC_TEST
Intervention: FLT-PET/CT
Description: Standard of Care

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET/CT
Description: Standard of Care

Intervention type: DRUG
Intervention: FLT
Description: 5 mCi IV
Study: NCT02506933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01151722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bevacizumab injection
Description: bevacizumab injection before vitrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bevacizumab injection
Description: bevacizumab injection after vitrectomy
Study: NCT01795547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and aripiprazole once-monthly
Description: Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone and paliperidone palmitate
Description: Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
Study: NCT03924401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
Study: NCT02004002

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance with normal protein intake
Description: Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintenance with protein restriction
Description: Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
Study: NCT04469192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
Study: NCT01428466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2585823
Description: CLDM1%/BPO3%
Study: NCT02205489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01428466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide 3%
Description: Benzoyl peroxide 3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide 5%
Description: Benzoyl peroxide 5%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: placebo
Study: NCT03056105

Intervention type: OTHER
Intervention: Residential Insight Meditation Retreat
Description: Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet.
Study: NCT02205489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04276324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Ten weeks of resistance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing sessions
Description: Testing sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing sessions
Description: Testing sessions
Study: NCT01783067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pearl millet
Description: Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified pearl millet
Description: Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.